PRN: Biosimilars Market Access in Psoriasis 2017 - Physicians Hesitant to Use Biosimilars, But Understand that Payers May Hold Sway - Research and Markets

18/mag/2017 20.15.11 PR Newswire Turismo Contatta l'autore

Biosimilars Market Access in Psoriasis 2017 - Physicians Hesitant to Use Biosimilars, But Understand that Payers May Hold Sway - Research and Markets

 
[18-May-2017]
 

DUBLIN, May 18, 2017 /PRNewswire/ --

Dublin - Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriasis" report to their offering.

Research and Markets Logo

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent biosimilar launches.

Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors. This rate of erosion may initially be gradual, as neither physicians nor payers are likely to advocate patient switching.

Key Topics Covered:

1. Executive Summary

  • Insights and strategic recommendations
  • Inflectra carries biosimilar labeling designation, but is not interchangeable
  • Physicians hesitant to use biosimilars, but understand that payers may hold sway
  • Bibliography

2. Five Major EU Markets

  • Insights and strategic recommendations
  • Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
  • Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
  • Payers use biosimilars to pressure originators on pricing
  • Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
  • Biosimilars will be used as price benchmarks for pipeline agents
  • Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
  • Bibliography

3. Methodology

  • Primary research

For more information about this report visit http://www.researchandmarkets.com/research/dr3pv9/biosimilars

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus
Comunicati.net รจ un servizio offerto da Factotum Srl